<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02352675</url>
  </required_header>
  <id_info>
    <org_study_id>P00016186</org_study_id>
    <nct_id>NCT02352675</nct_id>
  </id_info>
  <brief_title>Determination of the Minimal Concentration of Antifibrinolytics Required to Inhibit t-PA-activated Fibrinolysis</brief_title>
  <official_title>Determination of the Minimal Concentration of Antifibrinolytics Required to Inhibit t-PA-activated Fibrinolysis Using an in Vitro Experimental Model of Fibrinolysis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Children’s Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Children’s Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Lysine analogs, like tranexamic acid (TXA) or epsilon aminocaproic acid (EACA), are
      antifibrinolytic agents routinely administered in children undergoing different surgeries
      associated with a high bleeding risk (e.g. cardiac, craniofacial, and orthopedic surgeries).
      Although there is a growing literature regarding the pharmacokinetic characteristics of these
      drugs in children, the plasmatic concentration required to completely inhibit fibrinolysis
      remains to be determined. In this in vitro study, the investigators will use an experimental
      model of fibrinolysis designed for rotational thromboelastometry (ROTEM®) to determine the
      minimal concentration inhibiting fibrinolysis for both TXA and EACA. In addition, this study
      will be used to create and validate a new experimental assay to measure fibrinolysis and the
      effect of antifibrinolytic agents.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Concentration of antifibrinolytics associated with a complete inhibition of t-PA activated fibrinolysis confirmed by EXTEM test and the Star-TEM test.</measure>
    <time_frame>One Year</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">40</enrollment>
  <condition>Congenital Heart Disease</condition>
  <condition>Fibrinolysis</condition>
  <condition>Rotational Thromboelastometry</condition>
  <arm_group>
    <arm_group_label>Congenital Heart Disease</arm_group_label>
    <description>Infants with congenital heart disease (CHD) who are scheduled to undergo an elective cardiac catheterization lab procedure at Boston Children's Hospital</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non Congenital Heart Disease</arm_group_label>
    <description>Infants who do not have congenital heart disease (No-CHD) and are scheduled to undergo a non-cardiac surgery (such as craniofacial surgery, neurosurgery, or orthopedic surgery) in the operating room at Boston Children's Hospital.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Intraoperative Blood Sample</intervention_name>
    <description>Blood sample will be run using rotational thromboelastometry to determine the minimal concentration of TXA and EACA need to inhibit fibrinolysis</description>
    <arm_group_label>Congenital Heart Disease</arm_group_label>
    <arm_group_label>Non Congenital Heart Disease</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      The doctor will obtain one 13.6 mL blood sample from the arterial catheter or intravenous
      catheter at the beginning of the procedure after the patient has been anesthetized.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        This is a prospective in vitro study being performed on whole blood obtained from two
        groups of infants. The first group will include infants with congenital heart disease (CHD)
        who are scheduled to undergo an elective cardiac catheterization lab procedure at Boston
        Children's Hospital. The second group will include infants who do not have congenital heart
        disease (No-CHD) and are scheduled to undergo a non-cardiac surgery (such as craniofacial
        surgery, neurosurgery, or orthopedic surgery) in the operating room at Boston Children's
        Hospital.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  infants between 2 months of age and equal to or less than 12 months of age

          -  weigh over 5.0 kg

          -  either have CHD and are scheduled to undergo an elective cardiac catheterization lab
             procedure or do not have CHD and are scheduled to undergo a non-cardiac surgery (such
             as craniofacial surgery, neurosurgery, or orthopedic surgery) in the operating room

        Exclusion Criteria:

          -  undergoing an emergent procedure,

          -  child in a moribund condition (American Society of Anesthesiology (ASA 5)

          -  children with a hematological and/or oncological disease

          -  Jehovah witnesses

          -  children with preoperative coagulopathy, defined as a platelet count &lt; 100,000/μL,
             fibrinogen level &lt; 100 mg/dL, prothrombin time (PT) and activated partial
             thromboplastin time (PTT) &gt; 1.5 normal range
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Months</minimum_age>
    <maximum_age>12 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Faraoni, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Boston Children’s Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Boston Children's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Miller BE, Mochizuki T, Levy JH, Bailey JM, Tosone SR, Tam VK, Kanter KR. Predicting and treating coagulopathies after cardiopulmonary bypass in children. Anesth Analg. 1997 Dec;85(6):1196-202.</citation>
    <PMID>9390579</PMID>
  </reference>
  <reference>
    <citation>Arnold P. Treatment and monitoring of coagulation abnormalities in children undergoing heart surgery. Paediatr Anaesth. 2011 May;21(5):494-503. doi: 10.1111/j.1460-9592.2010.03461.x. Epub 2010 Dec 1. Review.</citation>
    <PMID>21118327</PMID>
  </reference>
  <reference>
    <citation>Ngaage DL, Bland JM. Lessons from aprotinin: is the routine use and inconsistent dosing of tranexamic acid prudent? Meta-analysis of randomised and large matched observational studies. Eur J Cardiothorac Surg. 2010 Jun;37(6):1375-83. doi: 10.1016/j.ejcts.2009.11.055. Epub 2010 Feb 1. Review.</citation>
    <PMID>20117944</PMID>
  </reference>
  <reference>
    <citation>Eaton MP. Antifibrinolytic therapy in surgery for congenital heart disease. Anesth Analg. 2008 Apr;106(4):1087-100. doi: 10.1213/ane.0b013e3181679555. Review.</citation>
    <PMID>18349177</PMID>
  </reference>
  <reference>
    <citation>Faraoni D, Willems A, Melot C, De Hert S, Van der Linden P. Efficacy of tranexamic acid in paediatric cardiac surgery: a systematic review and meta-analysis. Eur J Cardiothorac Surg. 2012 Nov;42(5):781-6. doi: 10.1093/ejcts/ezs127. Epub 2012 Apr 24. Review.</citation>
    <PMID>22531271</PMID>
  </reference>
  <reference>
    <citation>Faraoni D, Goobie SM. New insights about the use of tranexamic acid in children undergoing cardiac surgery: from pharmacokinetics to pharmacodynamics. Anesth Analg. 2013 Oct;117(4):760-2. doi: 10.1213/ANE.0b013e3182a22278.</citation>
    <PMID>24057950</PMID>
  </reference>
  <reference>
    <citation>Faraoni D. Safety of tranexamic acid in pediatric cardiac surgery: what we do not know. Eur J Cardiothorac Surg. 2011 Dec;40(6):1550-1; author reply 1551-2. doi: 10.1016/j.ejcts.2011.03.009. Epub 2011 Apr 14.</citation>
    <PMID>21497106</PMID>
  </reference>
  <reference>
    <citation>Raza I, Davenport R, Rourke C, Platton S, Manson J, Spoors C, Khan S, De'Ath HD, Allard S, Hart DP, Pasi KJ, Hunt BJ, Stanworth S, MacCallum PK, Brohi K. The incidence and magnitude of fibrinolytic activation in trauma patients. J Thromb Haemost. 2013 Feb;11(2):307-14. doi: 10.1111/jth.12078.</citation>
    <PMID>23176206</PMID>
  </reference>
  <reference>
    <citation>Dekker SE, Viersen VA, Duvekot A, de Jong M, van den Brom CE, van de Ven PM, Schober P, Boer C. Lysis onset time as diagnostic rotational thromboelastometry parameter for fast detection of hyperfibrinolysis. Anesthesiology. 2014 Jul;121(1):89-97. doi: 10.1097/ALN.0000000000000229.</citation>
    <PMID>24646494</PMID>
  </reference>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 26, 2015</study_first_submitted>
  <study_first_submitted_qc>January 28, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 2, 2015</study_first_posted>
  <last_update_submitted>July 28, 2017</last_update_submitted>
  <last_update_submitted_qc>July 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Boston Children’s Hospital</investigator_affiliation>
    <investigator_full_name>David Faraoni</investigator_full_name>
    <investigator_title>Cardiac Anesthesiologist</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antifibrinolytic Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

